Results of Cox proportional hazards regression analysis of the effect of baseline variables on long-term survival; outcome is death within follow-up of 180 days, patients lost to follow-up were censored
Baseline variables | HR (95% CI) | p Value |
Univariate analysis | ||
MR-proANP (>102 pmol/l) | 10.98 (6.90 to 17.47) | <0.0001 |
CT-proAVP (>22.3 pmol/l) | 6.47 (4.69 to 8.94) | <0.0001 |
CRB-65 (>1) | 4.25 (3.14 to 5.77) | <0.0001 |
Congestive heart failure | 3.67 (2.70 to 4.99) | <0.0001 |
Comorbidity* | 7.62 (4.50 to 12.92) | <0.0001 |
Multivariate Cox regression model 1 | ||
MR-proANP (>102 pmol/l) | 7.67 (4.72 to 12.45) | <0.0001 |
CRB-65 (>1) | 2.43 (1.78 to 3.32) | <0.0001 |
Congestive heart failure | 1.64 (1.19 to 2.25) | 0.002 |
Multivariate Cox regression model 2 | ||
MR-proANP (>102 pmol/l) | 6.37 (3.92 to 10.35) | <0.0001 |
CRB-65 (>1) | 2.28 (1.67 to 3.11) | <0.0001 |
Comorbidity* | 3.23 (1.87 to 5.59) | <0.001 |
Multivariate Cox regression model 3 | ||
CT-proAVP (>22.3 pmol/l) | 4.43 (3.18 to 6.17) | <0.0001 |
CRB-65 (>1) | 2.38 (1.74 to 3.25) | <0.0001 |
Comorbidity* | 4.65 (2.71 to 7.96) | <0.0001 |
↵* Presence of one or more comorbidities: congestive heart failure, chronic obstructive pulmonary disease, chronic renal disease, chronic liver disease, cerebrovascular disease, malignancy, or diabetes mellitus.
CT-proAVP, C-terminal pro-atrial vasopressin; MR-proANP, mid-regional pro-atrial natriuretic peptide.